01—Abstract
Summary
Summary of the 10-Q filed October 29, 2025. Cited figures are marked; the original filing is the authoritative source.
CVS Health's Q3 2025 10-Q shows a sharply weaker quarter on a GAAP basis, driven by a $5.7 billiona non-cash goodwill impairment on its Health Care Delivery reporting unit (Signify Health and Oak Street Health).
Revenue still grew 7.8% year over year to $102.9 billionb, and the Health Care Benefits segment swung from an adjusted operating loss of $924 million to adjusted operating income of $314 million, helped by an improved medical benefit ratio of 92.8% versus 95.2%. Consolidated GAAP operating results were a loss of $3.2 billion, and the company posted a net loss attributable to CVS Health of $3.98 billion, or $(3.13) per share, versus net income of $87 million a year earlier. The nine-month picture is also weaker, with a net loss of $1.2 billion, driven by the impairment, $1.2 billion of legacy litigation charges, a $320 million opioid charge, and losses tied to the wind-down of Accountable Care assets.
The quarter also included a $483 millionc gain from deconsolidating Omnicare after its September 2025 Chapter 11 filing. Operating cash flow was roughly flat at $7.2 billion for the nine months, and the company kept its $0.665 quarterly dividend. Management flagged continued elevated utilization, Medicaid cost pressure, and the planned exit from individual exchange markets in January 2026.
The impairment note also says the remaining Health Care Delivery goodwill of about $4.2 billiond has no headroom, so further impairment is reasonably possible if forecasts are missed. Debt ratings remain investment grade (BBB/Baa3/BBB), though the S&P and Fitch outlooks are negative.
For investors, the central questions are whether the Health Care Benefits margin recovery is durable through the 2026 Medicare Advantage bid cycle, whether Health Care Delivery can deliver its revised projections, and how much pending litigation (including the appeals of the $291 million PBM judgment and the Omnicare False Claims Act penalties) could ultimately cost. The company has about $9.1 billion of cash and $64.6 billion of long-term debt principal, so liquidity is not the immediate concern, but the earnings volatility and the negative outlook warrant close monitoring.
02—Key points
Key Highlights
- GAAP operating loss of $3.2 billion in Q3 2025, driven by a $5.7 billion goodwill impairment in the Health Care Delivery reporting unit (non-deductible for tax); this compares with operating income of $832 million in Q3 2024.
- Net loss attributable to CVS Health of $(3.98) billion, or $(3.13) per diluted share, versus net income of $87 million ($0.07 per share) a year earlier.
- Total revenues grew 7.8% to $102.9 billion, led by Health Services (+11.6%, pharmacy drug mix and brand inflation) and Health Care Benefits (+9.1%, Medicare Part D under the IRA).
- Health Care Benefits adjusted operating income of $314 million versus a $924 million loss a year earlier, with MBR improving to 92.8% from 95.2% on premium deficiency reserve timing and favorable prior-period development.
- Omnicare deconsolidated after its September 22, 2025 Chapter 11 filing, producing a $483 million one-time gain; the retained equity interest is carried at $0.
- Nine-month operating cash flow of $7.2 billion was flat year over year; cash and equivalents were $9.1 billion, and long-term debt was about $60.5 billion (non-current), with ratings unchanged at BBB/Baa3/BBB and negative outlooks at Fitch and S&P.
- Remaining Health Care Delivery goodwill of about $4.2 billion has no fair value headroom, and management says further impairment is reasonably possible if forecasts are not met; the company also plans to exit individual exchange markets effective January 2026.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q3 FY2025, CVS Health Corp lost $0.04.
- Revenue$102.87B100.0%
- Cost of revenue−$57.05B55.5%
- Gross profit$45.83B44.5%
- Operating costs−$49.03B47.7%
- Operating income−$3.21B3.1%
- Interest, other & tax−$768.0M0.7%
- Net income−$3.98B3.9%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 29, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $102.87B$95.43B | +7.8% |
| Cost of Revenue | $57.05B$52.95B | +7.7% |
| Gross Profit | $45.83B$42.48B | +7.9% |
| Operating Expenses | $106.08B$94.60B | +12.1% |
| Operating Income | -$3.21B$832.00M | −485.5% |
| Net Income | -$3.98B$71.00M | −5698.6% |
| EPS (Basic) | $-3.13$0.07 | −4571.4% |
| EPS (Diluted) | $-3.13$0.07 | −4571.4% |
| Shares Outstanding (Basic) | 1.27B1.26B | +0.8% |
| Shares Outstanding (Diluted) | 1.27B1.26B | +0.8% |
05—Questions
Frequently Asked Questions
Why did CVS report a large net loss in Q3 2025 when the core insurance business improved?
The loss was driven mainly by a non-cash $5.7 billion goodwill impairment tied to the Health Care Delivery unit (Signify Health and Oak Street Health), which was lowered by weaker projections and lower peer valuation multiples. The impairment is not tax-deductible, which pushed the effective tax rate to (14.6)% for the quarter. Excluding the impairment and other special items, adjusted operating income rose in Health Care Benefits, which the company attributes to better medical cost performance and favorable prior-period development.
Is the Health Care Benefits margin recovery sustainable?
The company credits the MBR improvement to the absence of the large premium deficiency reserves recorded in Q3 2024, to higher favorable prior-period development, and to better Government business performance. Management warns that utilization stayed elevated through Q3 2025 and may keep pressuring results, that Medicaid acuity is rising faster than state rate updates, and that individual exchange higher acuity and Medicare Part D seasonality under the IRA will weigh on results. Further utilization beyond projections could require additional premium deficiency reserves, so the margin gain should be viewed as uncertain.
What are the biggest legal and regulatory risks disclosed?
Key exposures include the Omnicare False Claims Act judgment (about $165 million for which CVS is jointly liable, under appeal to the Second Circuit), a $291 million False Claims Act judgment on PBM reporting practices (under appeal to the Third Circuit), ongoing opioid litigation (not reasonably estimable in total), PBM rebate-related multi-district litigation and an FTC administrative complaint, and CMS RADV audits of Medicare Advantage contracts that could lead to retroactive premium refunds. The company states it cannot estimate the full range of possible loss for all opioid matters.
Does CVS have the liquidity and balance sheet capacity to absorb these pressures?
Liquidity appears adequate for the near term: cash and equivalents were about $9.1 billion (of which about $2.3 billion sat at the parent or unrestricted subsidiaries), the company has $7.5 billion of undrawn back-up credit facilities supporting its commercial paper program, and nine-month operating cash flow was $7.2 billion. Dividends of about $2.55 billion were paid in the nine months, and no buybacks were made. Credit ratings remain investment grade, but S&P and Fitch have negative outlooks, so future borrowing costs could rise if earnings or leverage deteriorate further.
What should investors watch in the coming quarters?
Investors should watch the Health Care Delivery reporting unit for further impairment and the Oak Street clinic closures planned for 2026; the Medicare Advantage RADV audit results, especially given that the 2026 star-rating bonus eligibility dropped to 81% of members from 88%; the Medicaid cost trend and rate updates; the effect of exiting individual exchange markets in January 2026; and the outcome of the appeals and of legacy litigation charges. Any new premium deficiency reserves or litigation accruals would again affect GAAP results substantially.
06—Continue